Package 0003-7125-11

{"route": ["INTRAVENOUS"], "spl_id": "1150d07b-4d33-4285-a242-1ecf12ed5a4c", "openfda": {"nui": ["N0000191260", "N0000191259", "N0000194003", "N0000194002"], "unii": ["31YO63LBSN", "AF75XOF6W3"], "rxcui": ["2596778", "2596784"], "spl_set_id": ["b22c9d83-3256-4e17-85f7-f331a504adc6"], "pharm_class_epc": ["Programmed Death Receptor-1 Blocking Antibody [EPC]", "Lymphocyte Activation Gene-3 Blocker [EPC]"], "pharm_class_moa": ["Programmed Death Receptor-1-directed Antibody Interactions [MoA]", "Lymphocyte Activation Gene-3 Antagonists [MoA]"], "manufacturer_name": ["E.R. Squibb & Sons, L.L.C."], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "1 VIAL, SINGLE-DOSE in 1 CARTON (0003-7125-11)  / 20 mL in 1 VIAL, SINGLE-DOSE", "package_ndc": "0003-7125-11", "marketing_start_date": "20220318"}], "brand_name": "OPDUALAG", "product_id": "0003-7125_1150d07b-4d33-4285-a242-1ecf12ed5a4c", "dosage_form": "INJECTION", "pharm_class": ["Lymphocyte Activation Gene-3 Antagonists [MoA]", "Lymphocyte Activation Gene-3 Blocker [EPC]", "Programmed Death Receptor-1 Blocking Antibody [EPC]", "Programmed Death Receptor-1-directed Antibody Interactions [MoA]"], "product_ndc": "0003-7125", "generic_name": "nivolumab and relatlimab-rmbw", "labeler_name": "E.R. Squibb & Sons, L.L.C.", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "OPDUALAG", "active_ingredients": [{"name": "NIVOLUMAB", "strength": "12 mg/mL"}, {"name": "RELATLIMAB", "strength": "4 mg/mL"}], "application_number": "BLA761234", "marketing_category": "BLA", "marketing_start_date": "20220318", "listing_expiration_date": "20261231"}